<SEC-DOCUMENT>0001493152-24-035581.txt : 20240910
<SEC-HEADER>0001493152-24-035581.hdr.sgml : 20240910
<ACCEPTANCE-DATETIME>20240910070008
ACCESSION NUMBER:		0001493152-24-035581
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240910
FILED AS OF DATE:		20240910
DATE AS OF CHANGE:		20240910

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OKYO Pharma Ltd
		CENTRAL INDEX KEY:			0001849296
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41386
		FILM NUMBER:		241288723

	BUSINESS ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
		BUSINESS PHONE:		44 (0) 207 495 2379

	MAIL ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO RULE 13a-16 OR 15d-16</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>September
2024</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
File Number:</B> 001-41386</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>OKYO
Pharma LTD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in Its Charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; color: #202124"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>9<SUP>th
</SUP>Floor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; color: #202124"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>107
Cheapside</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; color: #202124"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>London</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; color: #202124"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>EC2V
6DN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of registrant&rsquo;s principal executive office)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746; Form 40-F &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
CONTAINED IN THIS REPORT ON FORM 6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 10, 2024, OKYO Pharma LTD (the &ldquo;<U>Company</U>&rdquo;) issued this 6K announcing today that it has been notified that
Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 50,000 of
the Company&rsquo;s ordinary shares on NASDAQ at a price of US$1.03 per share. This brings the total shareholding of Mr Cerrone to 9,851,570
shares which is 29.12% of issued share capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being
furnished and shall not be deemed &ldquo;filed&rdquo; for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise
subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under
the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly
set forth by specific reference in such a filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
    Pharma LTD</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    September 10, 2024</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Keeren Shah</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keeren
    Shah</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><A HREF="ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">News Announcement, dated September 10, 2024</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; color: Red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; color: Red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; color: Red"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; color: Red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
Pharma Announces Chairman Acquires Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1A1A1A; background-color: white"><B>London
and New York, NY, September 10, 2024</B> &ndash; OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing
innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular
segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy,
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announced today that it has been notified that Panetta
Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 50,000 of the Company&rsquo;s
ordinary shares on NASDAQ at a price of US$1.03 per share. This brings the total shareholding of Mr Cerrone to 9,851,570 shares which
is 29.12% of issued share capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white; color: #1A1A1A"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
OK-101</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white; color: #1A1A1A"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white; color: #1A1A1A"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OK-101
is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of
the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide technology to produce a novel
long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing efficacy
signals in mouse models of dry eye disease and corneal neuropathic pain (NCP), respectively, and is designed to combat washout through
the inclusion of the lipid anchor built into the drug molecule to enhance the residence time of OK-101 within the ocular environment.
OK-101 recently showed statistical significance in multiple endpoints in a recently completed Phase 2, multi-center, double-blind, placebo-controlled
trial of OK-101 to treat DED.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white; color: #1A1A1A"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white; color: #1A1A1A"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
OKYO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white; color: #1A1A1A"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1A1A1A">OKYO
Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED
and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel
molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway
for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. For further information, please
visit </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>www.okyopharma.com</U><FONT STYLE="color: #1A1A1A">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Enquiries:</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
    Pharma Limited</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
    S. Jacob, Chief Executive Officer</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">917-497-7560</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Business
    Development &amp; Investor Relations</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    Spencer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+44
    (0)20 7495 2379</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !? 6\# 2(  A$! Q$!_\0
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M/YGL]%<]X?\ &FB>) %LKG;<8YMY?E?\!W_"NAJCSYPE!\LE9A11100%%%%
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M?_BJ]1\ J$\ Z$%&!]BC_E715A/$U.9V9K&A"RN>&?\ #/DW_0PQ_P#@*?\
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MW'Q;J_\ R&K[_KXD_P#0C7T!\!_^1'NO^OY__05KP+7(VBU_48V&&6ZE!'_
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M"<I$S=]$>G:<"-+M WWA"F?^^17(+>&'XRR6RD;9]+4,/<,2/T_G7;DA1DX
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?"/,,+%(I1QNSC&TXQGZ&O<J***D^>7-8(0Y5:Y__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
